US › Healthcare

RenovoRx Inc (RNXT)

US · Healthcare · Biotechnology

$1.04-1.89%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$563,000
Revenue YoY
+185.8%
Net profit
$-3.5M
Profit YoY
-45.5%
EPS
$-0.08
EPS estimate
$-0.08
Net margin
-625.4%

EPS came in at -0.08 against a street estimate of -0.08 — a beat of 0.0%.

Key statistics

Market cap
$43.2M
Forward P/E
0.0
P/B
3.84
Book value
$0.25
EPS (TTM)
$-0.33
52-week high
$1.45
52-week low
$0.70
50-day MA
$0.91
200-day MA
$0.94
Beta
0.99

Analyst view

Analysts rate RenovoRx Inc a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $7.03.

Shareholding

Insiders
3.42%
Institutions
18.82%

Largest institutional holders

FundStake
AIGH Capital Management, LLC8.22%
Bleichroeder LP3.69%
Vanguard Capital Management, LLC3.21%
Geode Capital Management, LLC0.85%
Sontag Advisory LLC0.56%
Citadel Advisors Llc0.52%
Vanguard Fiduciary Trust Co0.35%
Northwestern Mutual Wealth Management Co0.22%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for RenovoRx Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.